Sentences with phrase «data on treatment»

We collected data on treatment type (pump vs. injection) from adolescents» medical records because use of insulin pumps in adolescents has been associated with improved glycemic control (Sherr & Tamborlane, 2008).

Data on treatment of individuals show 13 sessions on average; marital and relationship therapy (11.5 sessions on average) and family therapy (9 sessions on average) often require even fewer sessions.

Opportunities lie ahead in the creation of strong partnerships with patients to collect post-approval, real - world data on treatment outcomes, and in the use of patient - led registries to both cut drug development costs and generate data on disease history / treatment outcomes.

Not exact matches

Turner's cousin couldn't figure out why it was so difficult to find data on childhood leukemia treatments, considering that it seemed like a problem that could easily be solved by tech.

Spark Therapeutics» stock soared 20 % in Wednesday trading on the heels of its second quarter 2017 earnings report and some (very) early data on the gene therapy - focused firm's treatment for the blood disorder hemophilia A.

While it's been facing some sales problems on the former front, the biotech is now attempting to strengthen its position in the latter with solid new data for an HIV treatment cocktail combining bictegravir with emtricitabine / tenofovir alafenamide, two of its main drugs for the virus.

Net neutrality, or the notion that Internet service providers (ISPs) and governments should treat all online data equally, has raised many important considerations on whether the Internet should have so - called «fast lanes» that prioritize content based on the ability to pay — and «slow lanes» for providers who can't afford the special treatment.

For example, Watson for Oncology can summarize the key medical attributes of a cancer patient and rank the best treatment options based on the data it has access to.

The Finnish drug maker on Sunday presented results from phase I trial of a prostate cancer treatment, saying according the data it «has been well tolerated, with no significant treatment - related adverse events.»

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

However, NIB chief executive Mark Fitzgibbon says he wants to give consumers data on the volume of procedures doctors are doing as well as content that helps them think about their treatment.

Branch Managers are expected to visit or talk to each CHP at least once per month29 and collect data from CHPs on pregnancy registrations, treatments provided to children under 5, and other activities.30 Living Goods told us that during their field visits with CHPs, Branch Managers are expected to evaluate CHPs on several criteria: 31

A Comment on the Breadth of Mood Causality with Respect to Pro- and Anti-Corporate Sentiment Although the data available for this report pertain to government actions, results of social mood change with respect to the treatment of corporations are not confined to acts of the state.

In the conference I was just at we were brainstorming on how to integrate various sorts of data to help improve cancer diagnosis and treatment.

All of these cultural «truths» are in exact opposition to clear and overwhelming research and biographical data on the optimum care and treatment of children.

For the purposes of this economic evaluation, the forms were initially used in a related study funded by the National Institute of Health Research (NIHR) research for patient benefit programme «assessing the impact of a new birth centre on choice and outcome of maternity care in an inner city area,» which will be reported in full elsewhere, comparing the costs of care in a free standing midwifery unit with care in an obstetric unit in the same trust.16 The data collected included details of staffing levels, treatments, surgeries, diagnostic imaging tests, scans, drugs, and other resource inputs associated with each stage of the pathway through intrapartum and after birth care.

Or, in the case of the effectiveness of Dawn as a degreaser for stripping cloth diapers, we rely on the data provided by other industries and then apply that information to the treatment of cloth diapers.

«There was no difference in the number of contacts between the high - and low - frequency treatment groups for women with non-missing data on breastfeeding outcomes.

«Based on this data, we would think for most women who receive treatment, their depression should be treated and resolved in six months or less,» said Dr. James Murrough.

According to a Cochrane systematic review that was based on limited data (11), exercise alone is insufficient for weight loss, dietary restrictions alone or in combination with exercise can enhance postpartum weight loss, and combined treatment is thought to preserve lean body mass compared with dietary restriction alone and, therefore, is preferable.

Diagnostic tools and data on the strains of bacteria play a huge role in making targeted treatments effective.

It features comprehensive information designed to help patients choose the best place for their treatment, including data on hospital waiting times and cleanliness.

You go on to use data from the Journal of the AMA, writing a number of paragraphs on this subject as part of the «Fact check», however the AMA article is referring to health incidents, and says nothing about survival rates, treatment, etc..

Wilbur Ross, the US commerce secretary, made America's requirements for a trade deal clear earlier this month: Britain would need to dismantle EU regulations and agree to (typically much lower) US ones, on things like pharmaceuticals, data protection, chemical safety standards and meat treatment.

Supporting commercial lines businesses Progress on fixed fees for costs of noise - induced hearing loss claims Support for fair compensation for mesothelioma sufferers Expansion of the Insurance Fraud Bureau's scope to commercial liability Campaigning for solutions fit for our future Our Flood Free Homes campaign Forward thinking policy for data and cyber Engaging Government to support the role of income protection Delivery of Flood Re, a world first solution for affordable flood cover Fighting fraud Partnering with Government on the Insurance Fraud Taskforce Renewing the Insurance Fraud Enforcement Department Securing new insurer access to the DVLA registered owners database Influencing sensible regulation On Solvency II, we: Secured changes to secondary legislation Clarified treatment of deferred tax Negotiated a favourable calibration of the EIOPA's fundamental spread Supporting insurance businesses Pushing for sensible development of global capital standards Securing better targeted tax legislation Managing the impact of international financial reporting standardon fixed fees for costs of noise - induced hearing loss claims Support for fair compensation for mesothelioma sufferers Expansion of the Insurance Fraud Bureau's scope to commercial liability Campaigning for solutions fit for our future Our Flood Free Homes campaign Forward thinking policy for data and cyber Engaging Government to support the role of income protection Delivery of Flood Re, a world first solution for affordable flood cover Fighting fraud Partnering with Government on the Insurance Fraud Taskforce Renewing the Insurance Fraud Enforcement Department Securing new insurer access to the DVLA registered owners database Influencing sensible regulation On Solvency II, we: Secured changes to secondary legislation Clarified treatment of deferred tax Negotiated a favourable calibration of the EIOPA's fundamental spread Supporting insurance businesses Pushing for sensible development of global capital standards Securing better targeted tax legislation Managing the impact of international financial reporting standardon the Insurance Fraud Taskforce Renewing the Insurance Fraud Enforcement Department Securing new insurer access to the DVLA registered owners database Influencing sensible regulation On Solvency II, we: Secured changes to secondary legislation Clarified treatment of deferred tax Negotiated a favourable calibration of the EIOPA's fundamental spread Supporting insurance businesses Pushing for sensible development of global capital standards Securing better targeted tax legislation Managing the impact of international financial reporting standardOn Solvency II, we: Secured changes to secondary legislation Clarified treatment of deferred tax Negotiated a favourable calibration of the EIOPA's fundamental spread Supporting insurance businesses Pushing for sensible development of global capital standards Securing better targeted tax legislation Managing the impact of international financial reporting standards.

Critics of charter schools pounced on the data, claiming charter s were getting preferential treatment.

Data isn't collected by the Welsh Government on waiting times for these treatments, and no targets have ever been set, but some patients have reported waiting for up to two years for treatment.

By not collecting data on waiting times for these vital treatments, Labour Ministers are brushing this problem under the carpet.

DeepMind is not planning to automate clinical decisions — such as what treatments to give patients — but says it wants to support doctors by making predictions based on data that is too broad in scope for an individual to take in.

Additional data from this study, also presented at The International Liver CongressTM today in Barcelona, Spain, show that 97 % of patients with the same HCV genotype, but without scarred livers, achieved SVR12 after eight weeks on the same treatment without ribavirin (RBV).

As patients and revenues improved, so did competing technology and data on how patients fared in the years after treatment.

profile of NF B - regulated genes and to extract clinically relevant data that could potentially bear on optimal cancer prevention and treatment.

As data on proton treatments continued to dribble in, it was hard for Zietman to accept the implications of his own studies, which tracked patients» progress.

«Most of the existing data on hypofractionation, however, draws on cases of moderately accelerated radiation treatment of the prostate, in contrast to our study with more extreme hypofractionation.

To accurately test the hypothesis of a lower risk of recurrence with HRT, a new study led by investigators at Brigham and Women's Hospital published in European Urology Focus, performed a systematic review and meta - analysis, pooling available data, to assess whether an improved risk of recurrence could be demonstrated using HRT compared with CRT, in addition to assessing the relative impact of these two treatments on bladder and rectal function.

Overall, Chen said the data can help patients weigh their treatment options based on their own baseline health and on their priorities.

In Quebec, researchers established a patient registry in 2015 to collect demographic data on patients who use medical marijuana, the type and dose they take, and the conditions they're seeking treatment for, along with self - reports on benefits and adverse outcomes.

The scientists conclude that in mice «well - timed treatment with rIL - 27 improved lung injury and accelerated recovery without affecting viral clearance» and continue «these data demonstrate that IL - 27 has a unique role in controlling immunopathology without impacting on host defense, and might therefore represent a promising candidate for immunomodulatory therapy of viral pneumonia.»

The two DSSAT crop modules were evaluated using measured data on soil water and crop yield from four treatments: irrigated cotton without a cover crop, irrigated cotton with winter wheat as a cover crop, dryland cotton without a cover crop, and dryland cotton with a winter wheat cover crop at the Texas A&M AgriLife Research Station at Chillicothe from 2011 to 2015.

«Based on our findings, both imiquimod and fluorouracil are effective noninvasive treatments in most primary, low - risk superficial BCC, but the data provide no definite evidence for superiority of imiquimod to fluorouracil,» commented Dr. Roozeboom.

«In geographically large and densely populated countries like China, tools like Thermia can provide better on - the - ground disease surveillance than by relying on data that is only captured at the point of treatment in the clinic,» says Hswen.

Once he has the data, Swanton hopes to raise enough money to test treatment strategies based on evolution.

But devising treatment strategies based on insights from sequencing data, as was done for Dishman, requires «monumental shifts in how we share knowledge,» says Brian Druker, director of Oregon Health & Science University's (OHSU) Knight Cancer Institute.

For instance, an automatic, computer - based analysis of the anatomical data from the imaging revealed that new fibers in the spinal cord sprouted in another pattern depending on the course of treatment.

Complete data was available on 454 individuals (222 in the treatment group and 232 in a control group).

The study examined 328 patients with cervical cancer and 1,312 controls, matched on age and decade, who enrolled in a hospital - based case - control study drawn from 26,831 patients who received treatment at Roswell Park Cancer Institute and completed the Patient Epidemiology Data System questionnaire between 1982 and 1998.

Besides working at IBM's Thomas J. Watson Research Center in Yorktown Heights, New York, Meyer heads something called the DREAM challenges, contests that ask teams of computer scientists to solve outstanding biomedical problems, such as predicting the outcome of prostate cancer treatment based on clinical variables or detecting breast cancer from mammogram data.

Both groups also discussed various efforts to pool data from patients so researchers and clinicians can learn what treatments work on which patients.

She believes that as California collects data on how the boys do in treatment, other states will follow.

Shadi Yaghi, M.D., of Brown University, Providence, R.I., and colleagues analyzed data from 10 stroke centers across the United States to understand the natural history of thrombolysis - related sICH and to focus on the efficacy of various treatments used.